MX367364B - Formulaciones de lorazepam de liberación sostenida. - Google Patents

Formulaciones de lorazepam de liberación sostenida.

Info

Publication number
MX367364B
MX367364B MX2015008756A MX2015008756A MX367364B MX 367364 B MX367364 B MX 367364B MX 2015008756 A MX2015008756 A MX 2015008756A MX 2015008756 A MX2015008756 A MX 2015008756A MX 367364 B MX367364 B MX 367364B
Authority
MX
Mexico
Prior art keywords
lorazepam
sustained release
beads
release formulations
composition
Prior art date
Application number
MX2015008756A
Other languages
English (en)
Other versions
MX2015008756A (es
Inventor
Vachon Michael
A Saltel Douglas
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50064764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367364(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of MX2015008756A publication Critical patent/MX2015008756A/es
Publication of MX367364B publication Critical patent/MX367364B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica para administrar lorazepam en una forma prolongada se logra con las perlas farmacéuticas de lorazepam de liberación prolongada. La composición contiene típicamente perlas de lorazepam de liberación sostenida y perlas de lorazepam de liberación sostenida retardada. La composición puede proporcionar una dosificación una vez al día que mantiene un efecto terapéutico de 24 horas bajo condiciones de estado permanente.
MX2015008756A 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberación sostenida. MX367364B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750797P 2013-01-09 2013-01-09
US201361762833P 2013-02-08 2013-02-08
PCT/US2014/010854 WO2014110245A1 (en) 2013-01-09 2014-01-09 Sustained release formulations of lorazepam

Publications (2)

Publication Number Publication Date
MX2015008756A MX2015008756A (es) 2016-03-31
MX367364B true MX367364B (es) 2019-08-16

Family

ID=50064764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008756A MX367364B (es) 2013-01-09 2014-01-09 Formulaciones de lorazepam de liberación sostenida.

Country Status (30)

Country Link
US (3) US8999393B1 (es)
EP (1) EP2943185B1 (es)
JP (2) JP6039823B2 (es)
KR (1) KR102318274B1 (es)
CN (1) CN105209018B (es)
AU (1) AU2014205440B2 (es)
BR (1) BR112015016304A8 (es)
CA (1) CA2897302C (es)
CL (1) CL2015001920A1 (es)
CY (1) CY1123933T1 (es)
DK (1) DK2943185T3 (es)
ES (1) ES2856181T3 (es)
HR (1) HRP20210236T1 (es)
HU (1) HUE054005T2 (es)
IL (1) IL239777B (es)
LT (1) LT2943185T (es)
MX (1) MX367364B (es)
NZ (1) NZ710860A (es)
PE (1) PE20151432A1 (es)
PH (1) PH12015501534A1 (es)
PL (1) PL2943185T3 (es)
PT (1) PT2943185T (es)
RS (1) RS61857B1 (es)
RU (1) RU2678324C2 (es)
SG (1) SG11201505349RA (es)
SI (1) SI2943185T1 (es)
SM (1) SMT202100091T1 (es)
UA (1) UA117233C2 (es)
WO (1) WO2014110245A1 (es)
ZA (1) ZA201505082B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
WO2019089330A1 (en) * 2017-11-01 2019-05-09 Edgemont Pharmceuticals, Llc Trust Alcohol-resistant oral pharmaceutical compositions of lorazepam

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (es) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
AU552261B2 (en) * 1980-01-21 1986-05-29 Wellcome Foundation Limited, The Use of propiophenone derivatives as adjuncts to benzo- diazepine tranquillisers
KR850700212A (ko) * 1984-03-21 1985-12-26 죠지 드모트 서방성 약제학적 캼셀제
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
JP3140465B2 (ja) 1992-09-18 2001-03-05 山之内製薬株式会社 ハイドロゲル徐放性製剤
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
CA2322641C (en) * 1998-03-23 2010-02-16 General Mills, Inc. Encapsulation of components into edible products
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
EP1165054A4 (en) * 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
DE60232290D1 (de) 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
EP1499300B1 (en) 2002-04-29 2009-03-18 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
EA013433B1 (ru) * 2005-02-15 2010-04-30 Элан Фарма Интернэшнл Лтд. Аэрозольные и впрыскиваемые рецептуры лекарственных препаратов бензодиазепина, состоящего из наночастиц
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070071819A1 (en) 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
WO2007010369A2 (en) 2005-07-22 2007-01-25 Emcure Pharmaceuticals Limited Sustained release formulation of alprazolam
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP2009522272A (ja) * 2005-12-30 2009-06-11 ミドルブルック ファーマスーティカルス，インコーポレイテッド 薬剤送達のための胃内放出パルスシステム
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
ES2953390T3 (es) * 2006-08-31 2023-11-10 Adare Pharmaceuticals Inc Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008068584A2 (en) 2006-12-05 2008-06-12 University Of Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
WO2009137067A1 (en) * 2008-05-08 2009-11-12 Supernus Pharmaceuticals Inc. Controlled release formulations of alprazolam
WO2010053337A2 (ko) 2008-11-10 2010-05-14 (주)아모레퍼시픽 서방성 미립자 및 이의 제조방법
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
KR102318274B1 (ko) 2021-10-26
ES2856181T3 (es) 2021-09-27
UA117233C2 (uk) 2018-07-10
IL239777B (en) 2019-03-31
IL239777A0 (en) 2015-08-31
BR112015016304A2 (pt) 2017-07-11
PL2943185T3 (pl) 2022-01-17
PE20151432A1 (es) 2015-09-23
PT2943185T (pt) 2021-02-18
US8999393B1 (en) 2015-04-07
SG11201505349RA (en) 2015-08-28
US20160228378A1 (en) 2016-08-11
RU2678324C2 (ru) 2019-01-28
BR112015016304A8 (pt) 2018-01-23
SMT202100091T1 (it) 2021-03-15
ZA201505082B (en) 2021-04-28
KR20150118119A (ko) 2015-10-21
JP2016504390A (ja) 2016-02-12
HRP20210236T1 (hr) 2021-03-19
RU2015128915A (ru) 2017-02-10
MX2015008756A (es) 2016-03-31
CY1123933T1 (el) 2022-05-27
AU2014205440A1 (en) 2015-08-27
CL2015001920A1 (es) 2016-01-29
HK1213770A1 (zh) 2016-07-15
US20150174078A1 (en) 2015-06-25
PH12015501534B1 (en) 2015-10-05
HUE054005T2 (hu) 2021-08-30
PH12015501534A1 (en) 2015-10-05
CA2897302A1 (en) 2014-07-17
CN105209018B (zh) 2019-06-25
JP2017019880A (ja) 2017-01-26
DK2943185T3 (da) 2021-02-15
RS61857B1 (sr) 2021-06-30
WO2014110245A1 (en) 2014-07-17
EP2943185B1 (en) 2020-11-18
CA2897302C (en) 2022-05-31
AU2014205440B2 (en) 2018-07-05
LT2943185T (lt) 2021-03-10
NZ710860A (en) 2020-05-29
CN105209018A (zh) 2015-12-30
EP2943185A1 (en) 2015-11-18
JP6039823B2 (ja) 2016-12-07
SI2943185T1 (sl) 2021-04-30
US20150110874A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
IL272423A (en) Administration, use and therapeutic applications of the CRISPR-CAS system and preparations for targeting disorders and diseases by using particulate delivery components
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
EP3043824A4 (en) Modified therapeutic agents and compositions thereof
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2012DE00912A (es)
SG11201604119YA (en) Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses
AU201613322S (en) A Compliance Monitor for a Medicament Inhaler
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
PH12015501534A1 (en) Sustained release formulations of lorazepam
IL245015A0 (en) Medicinal composition containing icotinib for topical treatment of the skin and its use
PL3041837T3 (pl) Kryształ o specyficznym pokroju kryształu i kompozycja farmaceutyczna zawierająca ten kryształ jako składnik czynny
IL261929B (en) Stable pharmaceutical preparations for topical administration and their use
MX2015008757A (es) Formulaciones de lorazepam de liberacion controlada.
SG10201810093PA (en) Pharmaceutical composition for external use
EP2968011A4 (en) Compositions and methods for delivering therapeutic and imaging agents to the sinuses and middle ear
TWD166399S (zh) 飲料分配器之部分
AR094391A1 (es) Formulaciones de lorazepam de liberación sostenida
UA59396U (ru) Применение композиций нестероидных противовоспалительных средств с кофеином как препаратов с антиэкссудативной активностью
AU367396S (en) A compliance monitor for a medicament inhaler

Legal Events

Date Code Title Description
FG Grant or registration